Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocklatan Trial With Optical Coherence Tomography Study of Retinal Perfusion
NCT07174401Phase 4Not yet recruiting
- Sponsor
- Oregon Health & Science University
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of netarsudil + latanoprost in open-angle glaucoma (OAG) (2 arms), sponsored by Oregon Health & Science University. Primary endpoint: Nerve Fiber Layer Plexus Capillary Density. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
netarsudil + latanoprost
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT07174401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174401.